Kontafarma China Holdings Limited (HKG:1312)

Market Cap	150.89M +8.0%
Revenue (ttm)	914.71M +1.9%
Net Income	-427.85M
EPS	-0.08
Shares Out	5.59B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	864,000
Open	0.0260
Previous Close	0.0260
Day's Range	0.0260 - 0.0270
52-Week Range	0.0250 - 0.0480
Beta	-0.02
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About Kontafarma China Holdings

Kontafarma China Holdings Limited, an investment holding company, manufactures and sells chemical drugs, active pharmaceutical ingredients (API), and API intermediates in Mainland China, Singapore, Taiwan, and internationally. The company operates through Pharmaceutical Business and Fitness Business segments. It provides prescription drugs, including chemical drugs and prescribed traditional Chinese medicines; operates fitness and yoga centers, as well as franchise business; and provides management and consultation services for fitness and heal...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2011
• Employees: 636
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1312

Financial Performance

In 2025, Kontafarma China Holdings's revenue was 914.71 million, an increase of 1.92% compared to the previous year's 897.52 million. Losses were -427.85 million, 466.4% more than in 2024.